Peer-reviewedCC BY-NC-NDPrecision radiation oncology
Feasibility of Urethra-Sparing Ultra-Hypofractionated Three-Dose-Level Radiotherapy for Prostate Cancer with a Dominant Intraprostatic Lesion Abutting the High-Dose Avoidance Zone.
- 1Fondazione Istituto Oncologico del Mediterraneo Viagrande Italy.
- 2Department of Radiation Oncology REM Radioterapia srl Viagrande Italy.
- 3Department of Medicine and Surgery University Kore of Enna Enna Italy.
Abstract
This planning study evaluated ultra-hypofractionated three-dose-level radiotherapy for prostate cancer with a dominant intraprostatic lesion (DIL) abutting the urethral high-dose avoidance zone (HDAZ). Ten patients (30 volumetric modulated arc therapy [VMAT] plans) were re-planned with 25 Gy to the pelvis, 35 Gy to the prostate, and 50 Gy to the DIL in five fractions. All plans achieved coverage while keeping urethral doses below the 90 GyEQD2 threshold and meeting organ-at-risk constraints, irrespective of DIL size or HDAZ contact. The findings demonstrate the feasibility of urethra-sparing with effective DIL dose escalation, even in peri-HDAZ locations.
Related
- Six-Fraction Ultra-Hypofractionated Radiotherapy for Tumours Adjacent to or Involving the Brachial Plexus: A Retrospective Cohort Study.
- Dosimetric Feasibility of Hypofractionated Radiation Therapy with Simultaneously Integrated Central Boost for Retroperitoneal Sarcoma.
- Comparative Dosimetric Evaluation of Tomotherapy with a 1-cm Field Width versus Volumetric-modulated Arc Therapy for Whole-brain Radiotherapy with Hippocampal Avoidance
- Editorial: Next-generation radiotherapy for prostate cancer: precision, personalization, and technological advances
- Using artificial intelligence for clinical trial quality assurance in a multi-institutional neurovascular-sparing prostate radiotherapy trial
BibTeX
@article{muscato2026feasibility,
title = {{Feasibility of Urethra-Sparing Ultra-Hypofractionated Three-Dose-Level Radiotherapy for Prostate Cancer with a Dominant Intraprostatic Lesion Abutting the High-Dose Avoidance Zone.}},
author = {Annalisa Muscato and Denis La Fauci and Anna Viola and Valentina Zagardo and Gianluca Ferini},
journal = {Precision radiation oncology},
year = {2026},
month = oct,
doi = {10.1002/pro6.70104},
url = {https://europepmc.org/article/MED/42927354},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Feasibility of Urethra-Sparing Ultra-Hypofractionated Three-Dose-Level Radiotherapy for Prostate Cancer with a Dominant Intraprostatic Lesion Abutting the High-Dose Avoidance Zone.
AU - Annalisa Muscato
AU - Denis La Fauci
AU - Anna Viola
AU - Valentina Zagardo
AU - Gianluca Ferini
PY - 2026
DA - 2026/10/24
JO - Precision radiation oncology
DO - 10.1002/pro6.70104
UR - https://europepmc.org/article/MED/42927354
AB - This planning study evaluated ultra-hypofractionated three-dose-level radiotherapy for prostate cancer with a dominant intraprostatic lesion (DIL) abutting the urethral high-dose avoidance zone (HDAZ). Ten patients (30 volumetric modulated arc therapy [VMAT] plans) were re-planned with 25 Gy to the pelvis, 35 Gy to the prostate, and 50 Gy to the DIL in five fractions. All plans achieved coverage while keeping urethral doses below the 90 GyEQD2 threshold and meeting organ-at-risk constraints, irrespective of DIL size or HDAZ contact. The findings demonstrate the feasibility of urethra-sparing with effective DIL dose escalation, even in peri-HDAZ locations.
SN - 2398-7324
ER -